Premium
P1‐363: Not Yet MCI: How to Detect Subtle Cognitive Impairment?
Author(s) -
Chipi Elena,
Salvadori Nicola,
Eusebi Paolo,
Farotti Lucia,
Lisetti Viviana,
Frattini Giulia,
Baschieri Francesca,
Sepe Federica Nicoletta,
Luchetti Elisa,
Chiasserini Davide,
Calabresi Paolo,
Parnetti Lucilla
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1114
Subject(s) - cambridge neuropsychological test automated battery , neuropsychology , cohort , cognition , psychology , cognitive impairment , audiology , neuropsychological test , boston naming test , episodic memory , medicine , spatial memory , psychiatry , working memory
model for FR from the Baltimore Longitudinal Study of Aging (Grober et al, 2008). FR was stable up to 7 years before AD diagnosis, then declined steadily until 3 years when the rate doubled. Impaired TR, the core clinical phenotype of the IWG-2 criteria for prodromal AD, emerges at this time. The OMICs was applied to the FR and TR scores of 148 AD cases that developed out of 1448 Einstein Aging Study participants initially dementia-free. Each data wave was assigned to the stage predicted by the OMICs according to when in the preclinical or clinical period the assessment was conducted. Descriptive statistics were computed for FR and TR at each OMICs stage and spaghetti plots displayed the trajectory of FR and TR decline. Results:The prescribed ranges for FR and TR at each OMICs stage fell within the 95% CI of the mean FR and TR scores assigned to that stage (Table). Trajectories for FR and TR appear consistent with expectations: FR declined at 7-8 years with more rapid decline at 3 years (Figure 1); TR was unimpaired (>46) until 3 years before diagnosis when decline began (Figure 2). The look-up-table (Figure3) classifies patients into OMICs stages based on their FR and TR scores. A patient with 28 in FR and 47 in TR would be assigned to the pre-aMCI stage; a patient with 23 in FR and 45 in TR would be assigned to the prodromal stage. Conclusions:The results support our proposed OMICs model. Analyses are underway to determine how well the model prospectively classifies individuals into the prescribed stages. The ultimate objective is to enable more accurate diagnosis and serve as a cost-effective screening tool for secondary AD clinical trials. Grober, 2008, JINS, 14,266.